9. Outlook Therapeutics Inc. (NASDAQ:OTLK)
Closing Share Price $0.5930
Daily Increase 3.13%
Market Cap $144.36 Million
Outlook Therapeutics, Inc. (NASDAQ: OTLK) focuses on developing and commercializing treatments for retinal diseases. Its ophthalmic bevacizumab program gives the company a specific position within eye care, rather than broad exposure to the pharmaceutical industry. That distinction matters when assessing the commercial opportunity and the steps needed to bring a treatment into routine use.
The stock closed at $0.5930 after gaining 3.13%, producing a ranking score of 5.28. Its reported market capitalization of approximately $144.36 million also demonstrates why a sub-$1 share price should not be confused with the total value of a company. Outstanding shares have an important role in that calculation.
A recent announcement highlighted an application for a permanent reimbursement code for LYTENAVA. Reimbursement arrangements, launch execution, and financing therefore deserve close attention. The reported trailing net loss was approximately $61.12 million, making the transition toward a commercially sustainable operation central to this healthcare penny stock’s story.
